For the first time, Indian consumers can buy prescription drugs online in a country where prescription drug prices are notoriously high.
The move has been hailed by drug users and doctors alike as an opportunity for India’s fledgling pharmaceutical industry to gain traction in a global market where prices for drugs like generics are high.
But for patients and drug companies, the government’s move to launch online access is also a step back for India, where the cost of prescription drugs has risen dramatically.
In 2014, the country’s drug prices reached $1,700 per month.
But that has fallen to $750 in 2016, according to data from the Indian Council of Medical Research.
The government has said it plans to roll out a “one-stop shop” that will allow online prescription drug purchases for patients.
With a population of just 3.3 million, India’s healthcare sector is one of the least developed in the world.
With fewer than 500,000 doctors and hospitals, the healthcare sector relies heavily on referrals and patients’ referrals.
With this new policy, India is opening its first online pharmacy for prescription drugs.
The service, called SSRI drugs, will allow users to buy generic drugs with lower prices.
The website will be launched in six cities in the southern state of Kerala on November 17, the state health department said.
The health ministry also plans to launch a website in Chennai, which has one of India’s lowest patient density.
“It’s a very promising step forward,” said Prof Jayesh Kumar, a research fellow at the Institute of Health Services and Population Research in New Delhi.
“But the real challenge will be to scale up the service in India.”
With such high prescription drug costs in India, India has faced an epidemic of drug-related deaths and an increase in the number of prescriptions being filled.
In March, the World Health Organization reported that India has the world’s highest number of deaths related to drug use.
India’s pharmaceutical industry, meanwhile, has been struggling with an economic crisis and a shortage of pharmaceuticals, and has faced criticism for its poor quality.
In April, the ministry of health said that the state had the highest number for drug-associated deaths in the country.
Many drug manufacturers in India are struggling to maintain high production costs, which have resulted in their drugs being widely available.
“If the government can afford to subsidise a drug company, why not subsidise other pharmaceutical companies?” said Dr Anirban Shah, an associate professor at the University of California, San Diego.
“I don’t know what the answer is to that question.
If it’s a government that can afford it, why can’t they also subsidise the entire pharmaceutical industry?”
With India’s population of 4.5 billion people, the pharmaceutical industry is India’s largest.
But with the country facing a major financial crisis, the cost to produce drugs has increased dramatically, making them unaffordable for many patients.
The cost of a single drug rose from $300 in 2016 to $5,500 in 2017, according the government.
That has put pressure on the government to expand access to generic medicines.
The pharmaceutical industry has also faced criticism over the price of prescription medicines in the past.
“The government has tried to get rid of price controls and it hasn’t worked out,” said Dr. Shah.
“India is facing the biggest drug shortage in the history of the world and the country is facing a huge fiscal crisis.”
In April 2018, the Supreme Court ruled that a government scheme to subsidize generic drugs would not be allowed to go ahead.
This decision sparked protests across the country, and many doctors and health officials said the government should do something to address the shortage.
India has one drug company that is among the largest suppliers of generic medicines in India: Sanofi-Aventis.
The company, which makes the popular Tylenol and Dilaudid drugs, has a manufacturing plant in India and sells its drugs through generic pharmacies.
Sanofi has been criticized for not offering a “fair” price for the drug, and its competitors are offering similar prices.
In 2016, the Indian government announced a new initiative that will give the government an incentive to provide subsidies to manufacturers of generic drugs, according with the Times of India.
The scheme will give manufacturers an incentive of up to $300,000 for each generic drug sold.
“We’re hoping to get a fair price for medicines,” Sanofi’s president, Dr. Virendra Sharma, told the Times.
“There is a lot of pressure on us.”
But according to Dr. Kumar, the company will not get a good price from the government for its generic drugs.
“Sanofi-Acute has been a very successful company for the last 15 years.
It has been very successful with their generic drugs,” he said.
“So, they won’t be too happy with a subsidy of $300.”
With India facing an economic crunch, the new government’s policy may be